Search results
418 Results for 'Drug Development'
- Technologies (30)
- Collaborations (7)
- Team (0)
- News (297)
- Pages (0)
- Multimedia (84)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 30
-
DNA Nanoswitch Calipers for Single-Molecule Proteomics
DNA nanoswitch calipers are a first-of-their-kind research tool that leverage DNA’s unique molecular qualities to study post-translational modifications on proteins to unlock a new frontier of medicine. -
Ropirio: Novel Treatments Targeting the Lymphatic System
Ropirio is commercializing the world’s first drug that directly targets and reactivates lymph vessels, a portfolio of other lymph-targeting small molecules, and a preclinical platform for discovering more. -
AminoX: Making Better Protein Drugs, Quicker and Cheaper
AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition. -
DNA Nanostructures for Drug Delivery
Researchers at the Wyss Institute have developed two methods for building arbitrarily shaped nanostructures using DNA, with a focus on translating the technology towards nanofabrication and drug delivery applications. One proprietary nanofabrication technique, called “DNA-brick self-assembly,” uses short, synthetic strands of DNA that work like interlocking Lego® bricks. It capitalizes on the ability to program... -
DNA Nanoswitches: “Lab-on-a-Molecule” Drug Discovery
The Lab-on-a-Molecule platform leverages the Wyss Institute’s DNA nanotechnology technology for the high-throughput, low-cost screening of a wide range of chemical and biologic compounds to enable the discovery of first-in-class therapeutics for various conditions. -
Lactation Biologics: Increasing Milk Production for Healthier Babies
Lactation Biologics is developing a long-lasting, self-injectable treatment to help nursing mothers feed their babies naturally, helping them get the best nutrition possible in the face of climate disasters and supply chain disruptions.
Collaborations 7
-
Nucleic Acid Delivery Consortium
An academic-industry consortium focused on the challenge of delivering nucleic acid-based therapies to specific target organs, tissues, and cells. -
Brain Targeted Therapeutic Collaboration
Combine our shuttles with your drugs to create new brain targeted therapeutics for patients. -
Brain Shuttle Research Sponsorship & Licensing
Enabling brain-targeted drug development through non-exclusive licensing and pre-competitive research sponsorship. -
Bridging the Funding Gap for Brain Therapeutics
A unique opportunity to help develop a new generation of brain targeted drugs -
Brigham-Wyss DxA
The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests. -
Biomarker Discovery Laboratory (BDL)
Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration.
News 297
Multimedia 84
-
Video/AnimationCure ALD – Behind the Research | Alex LeNail – Safer Gene TherapyLearn about Wyss Postdoctoral Fellow Alex LeNail‘s background and how he plans to develop a safer gene therapy for ALD (adrenoleukodystrophy) patients. If successful, this could go to clinical trials and give families hope for a cure. This video series tells the story of the scientists behind the breakthroughs, and why community-driven fundraising is the... -
Audio/PodcastJames Collins: Doing Good Science with an Underdog Spirit – The Pulse PodcastJames J. Collins is a founding Core Faculty member at the Wyss Institute and the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT. Jim serves as a director at the MIT Jameel Clinic, a member of the Harvard-MIT Health Sciences & Technology Faculty, and a member of the Broad... -
Audio/PodcastBrain Shuttles: A New Path Into the Brain with James Gorman of the Wyss InstituteThe host of Business Trip, Matias Serebrinsky, interviews Wyss Senior Director of Translational R&D James (Jim) Gorman, M.D., Ph.D. Jim is a Principal Investigator of the Wyss Institute Brain Targeting Program (BTP). He leads a team developing new approaches to transport drugs through the blood-brain barrier (BBB) into the central nervous system. In this episode,... -
Video/AnimationFinding a Balance In Bipolar Disorder Through Drug Prediction and Organoid-Based Drug ScreeningCircaVent is a high-throughput drug screening platform that combines predictive algorithms, preclinical models, and human brain organoids to efficiently identify and test drugs that could treat the underlying causes of bipolar disorder. CircaVent is initially focused on addressing the circadian rhythm disruptions that are a common hallmark of BD, and could dramatically speed up the... -
Video/AnimationAtlantic Health Research Spotlight: Novel Anesthetics for Care in Battlefield and Disaster AreaThe Atlantic’s Health Summit returned to Boston in 2025 for their annual exploration of the urgent issues reshaping the healthcare landscape. The event showcased recent breakthroughs that are redefining medical practices and explored the challenges of scaling innovation and implementing sustainable solutions. Speakers explored early disease detection, novel anesthetics, pain management, AI and drug discovery,... -
Video/AnimationESCAPE BioengineeringA research team at the Wyss Institute and Boston University has developed ESCAPE, the first method that enables the engineering of tissues across multiple length scales, ranging from the diameter of a cell to the cm scale of a heart valve. Credit: Wyss Institute at Harvard University